• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
1AD
Click for more information
0.00% 1.8¢

ADALTA LIMITED - Announcements

Market Cap $11.51M  ! watchlist Created with Sketch. Add to my watchlist

AdAlta Limited is an Australia-based clinical-stage biotechnology company. The Company... AdAlta Limited is an Australia-based clinical-stage biotechnology company. The Company uses its i-body platform to discover and develop protein therapeutics addressing drug targets that are challenging for other technologies. The Company's first-in-class lead asset, AD-214, is being developed for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases, for which current therapies are sub-optimal. AD-214 is an Fc-Fusion protein that contains two AD-114 i-body molecules at the front end, that bind with high affinity to the human target, CXCR4. It is also engaged in developing i-body enabled Chimeric antigen receptor T cell (CAR-T) cells. It co-develops i-bodies as diagnostic imaging agents (i-PET imaging) against Granzyme B, a biomarker of response to immuno-oncology drugs.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
1AD Major shareholder fund expiry extended12/03/19
1AD Half Yearly Report and AccountsPRICE SENSITIVE28/02/19
1AD Collaboration with Excellerate Bioscience28/02/19
1AD Investor and analyst briefing presentation31/01/19
1AD Manufacturing updatePRICE SENSITIVE29/01/19
1AD Appendix 4C - quarterlyPRICE SENSITIVE22/01/19
1AD Appendix 3B21/01/19
1AD Change of Director's Interest Notice x 329/11/18
1AD Appendix 3B29/11/18
1AD Results of Annual General Meeting 28 November 201828/11/18
1AD AGM Presentation28/11/18
1AD Notice of Annual General Meeting/Proxy Form24/10/18
1AD Receipt of R&D Tax IncentivePRICE SENSITIVE24/10/18
1AD Appendix 4C - Quarter ended 30 September 2018PRICE SENSITIVE17/10/18
1AD Shareholder information sessions15/10/18
1AD Manufacturing UpdatePRICE SENSITIVE15/10/18
1AD Change of Registry Address: Automic P/L - Sydney Office28/09/18
1AD Appendix 4G and Corporate Governance Statement07/09/18
1AD Annual Report to shareholders07/09/18
1AD Preliminary Final ReportPRICE SENSITIVE28/08/18
1AD Appendix 3B - Release of Securities from Escrow22/08/18
1AD Appendix 3B15/08/18
1AD SPP completion15/08/18
1AD Biotech Meets Broker Presentation09/08/18
1AD Share Purchase Plan Closing08/08/18
1AD Release of Securities from Escrow02/08/18
1AD AdAlta Investor Conference Call Audio01/08/18
1AD Investor presentation and conference callPRICE SENSITIVE01/08/18
1AD Investor conference call and Q&A session26/07/18
1AD Change in substantial holding24/07/18
1AD Change in substantial holding23/07/18
1AD Cleansing Notice19/07/18
1AD Appendix 3B19/07/18
1AD Appendix 4C - Quarter ended 30 June 2018PRICE SENSITIVE16/07/18
1AD Share Purchase Plan16/07/18
1AD Share Purchase Plan - Cleansing Notice16/07/18
1AD Investor Presentation13/07/18
1AD Completion of Capital Raise - $4.25m to advance AD-214PRICE SENSITIVE13/07/18
1AD Trading HaltPRICE SENSITIVE11/07/18
1AD CEO discusses recent manufacturing update05/06/18
1AD Company Presentation (June 2018)05/06/18
1AD AdAlta secures key manufacturing agreements for AD-214PRICE SENSITIVE05/06/18
1AD Appendix 4C - Quarter Ended 31 March 2018PRICE SENSITIVE23/04/18
1AD Interview AdAlta CEO AD-21418/04/18
1AD Shareholder information sessions18/04/18
1AD Investor presentation18/04/18
1AD AdAlta to advance improved lung fibrosis therapy, AD-214PRICE SENSITIVE18/04/18
1AD Appendix 3B26/02/18
1AD Half Yearly Report and AccountsPRICE SENSITIVE21/02/18
1AD Publication of AD-114 data19/02/18
1AD Investor Presentation02/02/18
1AD Appendix 4C - quarterlyPRICE SENSITIVE29/01/18
1AD AdAlta collaborator awarded NHMRC grantPRICE SENSITIVE07/12/17
1AD Change of Director's Interest Notice04/12/17
1AD Appendix 3B04/12/17
1AD Change of Director's Interest Notice x 424/11/17
1AD Appendix 3B24/11/17
1AD Appendix 3B21/11/17
1AD AdAlta granted key Australian PatentPRICE SENSITIVE17/11/17
1AD Results of Meeting (Updated)14/11/17
1AD Results of Meeting14/11/17
1AD AGM Presentation14/11/17
1AD Commercial agreement with XL-proteinPRICE SENSITIVE13/11/17
1AD Conference Presentation13/11/17
1AD Conference PresentationPRICE SENSITIVE31/10/17
1AD AusBiotech Presentation23/10/17
1AD Appendix 4C - quarterlyPRICE SENSITIVE20/10/17
1AD Notice of Annual General Meeting/Proxy Form12/10/17
1AD Appointment of COO09/10/17
1AD Appendix 3B27/09/17
1AD Change of Director's Interest Notice25/09/17
1AD Appendix 3B25/09/17
1AD Results of multi-dose toxicology studyPRICE SENSITIVE19/09/17
1AD Release of Securities from Escrow12/09/17
1AD Appendix 4G and Corporate Governance Statement07/09/17
1AD Annual Report to shareholders07/09/17
1AD Conference Presentation04/09/17
1AD Preliminary Final ReportPRICE SENSITIVE21/08/17
1AD IPF Summit Presentation21/08/17
1AD Receipt of R&D Tax IncentivePRICE SENSITIVE07/08/17
1AD Appendix 4C - quarterlyPRICE SENSITIVE27/07/17
1AD Shareholder information sessions update24/07/17
1AD AdAlta awarded SIEF grantPRICE SENSITIVE24/07/17
1AD Bioshares Presentation21/07/17
1AD Shareholder information sessions20/07/17
1AD Toxicology study and manufacturing updatePRICE SENSITIVE18/07/17
1AD Change of Director's Interest Notice - Late lodgement14/07/17
1AD Company Secretary Appointment/Resignation31/05/17
1AD Presentation of Eye Fobrosis Data at ARVO MeetingPRICE SENSITIVE08/05/17
1AD Lonza Poster detailing i-body expression in yeastPRICE SENSITIVE08/05/17
1AD Investor Presentation03/05/17
1AD Appendix 4C - quarterlyPRICE SENSITIVE26/04/17
1AD Research Report10/04/17
1AD AdAlta expands partnership with Alfred HospitalPRICE SENSITIVE21/03/17
1AD Appendix 3B23/02/17
1AD Fibrosis symposium presentation21/02/17
1AD Half Yearly Report and AccountsPRICE SENSITIVE14/02/17
1AD Release of Securities from Escrow01/02/17
1AD Appendix 4C - quarterlyPRICE SENSITIVE31/01/17
1AD AdAlta receives Orphan Designation for AD-114PRICE SENSITIVE18/01/17
1AD Major shareholder fund expiry extended
12/03/19
1AD Half Yearly Report and Accounts
28/02/19PRICE SENSITIVE
1AD Collaboration with Excellerate Bioscience
28/02/19
1AD Investor and analyst briefing presentation
31/01/19
1AD Manufacturing update
29/01/19PRICE SENSITIVE
1AD Appendix 4C - quarterly
22/01/19PRICE SENSITIVE
1AD Appendix 3B
21/01/19
1AD Change of Director's Interest Notice x 3
29/11/18
1AD Appendix 3B
29/11/18
1AD Results of Annual General Meeting 28 November 2018
28/11/18
1AD AGM Presentation
28/11/18
1AD Notice of Annual General Meeting/Proxy Form
24/10/18
1AD Receipt of R&D Tax Incentive
24/10/18PRICE SENSITIVE
1AD Appendix 4C - Quarter ended 30 September 2018
17/10/18PRICE SENSITIVE
1AD Shareholder information sessions
15/10/18
1AD Manufacturing Update
15/10/18PRICE SENSITIVE
1AD Change of Registry Address: Automic P/L - Sydney Office
28/09/18
1AD Appendix 4G and Corporate Governance Statement
07/09/18
1AD Annual Report to shareholders
07/09/18
1AD Preliminary Final Report
28/08/18PRICE SENSITIVE
1AD Appendix 3B - Release of Securities from Escrow
22/08/18
1AD Appendix 3B
15/08/18
1AD SPP completion
15/08/18
1AD Biotech Meets Broker Presentation
09/08/18
1AD Share Purchase Plan Closing
08/08/18
1AD Release of Securities from Escrow
02/08/18
1AD AdAlta Investor Conference Call Audio
01/08/18
1AD Investor presentation and conference call
01/08/18PRICE SENSITIVE
1AD Investor conference call and Q&A session
26/07/18
1AD Change in substantial holding
24/07/18
1AD Change in substantial holding
23/07/18
1AD Cleansing Notice
19/07/18
1AD Appendix 3B
19/07/18
1AD Appendix 4C - Quarter ended 30 June 2018
16/07/18PRICE SENSITIVE
1AD Share Purchase Plan
16/07/18
1AD Share Purchase Plan - Cleansing Notice
16/07/18
1AD Investor Presentation
13/07/18
1AD Completion of Capital Raise - $4.25m to advance AD-214
13/07/18PRICE SENSITIVE
1AD Trading Halt
11/07/18PRICE SENSITIVE
1AD CEO discusses recent manufacturing update
05/06/18
1AD Company Presentation (June 2018)
05/06/18
1AD AdAlta secures key manufacturing agreements for AD-214
05/06/18PRICE SENSITIVE
1AD Appendix 4C - Quarter Ended 31 March 2018
23/04/18PRICE SENSITIVE
1AD Interview AdAlta CEO AD-214
18/04/18
1AD Shareholder information sessions
18/04/18
1AD Investor presentation
18/04/18
1AD AdAlta to advance improved lung fibrosis therapy, AD-214
18/04/18PRICE SENSITIVE
1AD Appendix 3B
26/02/18
1AD Half Yearly Report and Accounts
21/02/18PRICE SENSITIVE
1AD Publication of AD-114 data
19/02/18
1AD Investor Presentation
02/02/18
1AD Appendix 4C - quarterly
29/01/18PRICE SENSITIVE
1AD AdAlta collaborator awarded NHMRC grant
07/12/17PRICE SENSITIVE
1AD Change of Director's Interest Notice
04/12/17
1AD Appendix 3B
04/12/17
1AD Change of Director's Interest Notice x 4
24/11/17
1AD Appendix 3B
24/11/17
1AD Appendix 3B
21/11/17
1AD AdAlta granted key Australian Patent
17/11/17PRICE SENSITIVE
1AD Results of Meeting (Updated)
14/11/17
1AD Results of Meeting
14/11/17
1AD AGM Presentation
14/11/17
1AD Commercial agreement with XL-protein
13/11/17PRICE SENSITIVE
1AD Conference Presentation
13/11/17
1AD Conference Presentation
31/10/17PRICE SENSITIVE
1AD AusBiotech Presentation
23/10/17
1AD Appendix 4C - quarterly
20/10/17PRICE SENSITIVE
1AD Notice of Annual General Meeting/Proxy Form
12/10/17
1AD Appointment of COO
09/10/17
1AD Appendix 3B
27/09/17
1AD Change of Director's Interest Notice
25/09/17
1AD Appendix 3B
25/09/17
1AD Results of multi-dose toxicology study
19/09/17PRICE SENSITIVE
1AD Release of Securities from Escrow
12/09/17
1AD Appendix 4G and Corporate Governance Statement
07/09/17
1AD Annual Report to shareholders
07/09/17
1AD Conference Presentation
04/09/17
1AD Preliminary Final Report
21/08/17PRICE SENSITIVE
1AD IPF Summit Presentation
21/08/17
1AD Receipt of R&D Tax Incentive
07/08/17PRICE SENSITIVE
1AD Appendix 4C - quarterly
27/07/17PRICE SENSITIVE
1AD Shareholder information sessions update
24/07/17
1AD AdAlta awarded SIEF grant
24/07/17PRICE SENSITIVE
1AD Bioshares Presentation
21/07/17
1AD Shareholder information sessions
20/07/17
1AD Toxicology study and manufacturing update
18/07/17PRICE SENSITIVE
1AD Change of Director's Interest Notice - Late lodgement
14/07/17
1AD Company Secretary Appointment/Resignation
31/05/17
1AD Presentation of Eye Fobrosis Data at ARVO Meeting
08/05/17PRICE SENSITIVE
1AD Lonza Poster detailing i-body expression in yeast
08/05/17PRICE SENSITIVE
1AD Investor Presentation
03/05/17
1AD Appendix 4C - quarterly
26/04/17PRICE SENSITIVE
1AD Research Report
10/04/17
1AD AdAlta expands partnership with Alfred Hospital
21/03/17PRICE SENSITIVE
1AD Appendix 3B
23/02/17
1AD Fibrosis symposium presentation
21/02/17
1AD Half Yearly Report and Accounts
14/02/17PRICE SENSITIVE
1AD Release of Securities from Escrow
01/02/17
1AD Appendix 4C - quarterly
31/01/17PRICE SENSITIVE
1AD AdAlta receives Orphan Designation for AD-114
18/01/17PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
1.8¢ 		Change
0.000(0.00%) 		Mkt cap ! $11.51M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
3 718710 1.7¢
 

Sellers (Offers)

Price($) Vol. No.
1.9¢ 560699 4
View Market Depth
Last trade - 16.13pm 15/11/2024 (20 minute delay) ?
1AD (ASX) Chart

Top Stories

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

Copper prices slump; Trump Wall Street rally fades; US health stocks dip on RFK appointment – and much more.
HotCopper Highlights: Your most watched stocks for Week 46, 2024 What you - HotCopper users - were most interested in viewing and discussing this week (Week 46 of the year!)
CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch CuFe Ltd (ASX:CUF) has decided not to wait around for Northern Star's Crossroads mine to get up and running, selling its $4M royalty right.
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain InhaleRX Ltd has received approval for a Phase 2 clinical trial to test its novel therapy IRX-211 for treatment of Breakthrough Cancer Pain
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.